2024 SV Therapeutics Impact & ESG Report
Read More
Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas
Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System
SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System
Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise
Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –
Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix
Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure
Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More
SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion
Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation
QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics
SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner
Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership
Merck to Acquire Caraway Therapeutics, Inc.
EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases
SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
24 February 2021Portfolio NewsXilio Therapeutics Raises $95 Million in Series C Financing to Advance Potent Tumor-Selective Immuno-Oncology Pipeline
11 February 2021Portfolio NewsArtios Pharma Announces the Start of First Clinical Study with the Dosing of its ATR Inhibitor, ART0380, to Patients
26 January 2021Portfolio NewsBicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer- 12 January 2021Portfolio NewsArtios Pharma Appoints Abid Ansari as Chief Financial Officer
12 January 2021Portfolio NewsBoehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
6 January 2021Portfolio NewsRibometrix Announces Collaboration with Genentech to Discover and Develop RNA-Targeted Small Molecule Therapeutics- 16 December 2020Portfolio NewsEnara Bio adds further world‐class cell therapy and immuno‐oncology expertise to Senior Management Team and Scientific Advisory Board
- 9 December 2020Portfolio NewsEnara Bio relocates to The Oxford Science Park's newest facility to expand R&D capabilities in the search for novel cancer immunotherapies
- 3 December 2020Portfolio NewsMerck KGaA and Artios Pharma Announce a Global Strategic Collaboration on Novel DNA Damage Response Targets in Oncology
- 23 November 2020Portfolio NewsCatamaran Bio Launches with $42 Million Financing to Develop Off-the-Shelf CAR-NK Cell Therapies to Treat Solid Tumors
- 23 November 2020Portfolio NewsThe Boston Globe Names Deciphera a Top Place to Work for 2020
- 18 November 2020Portfolio NewsPionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314
